UOC
TARS icon

UBS O'Connor’s Tarsus Pharmaceuticals TARS Stock Holding History

UBS O'Connor’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,000
Closed -$446K – 432
2025
Q2 		$446K Buy
+11,000
New +$495K 0.01% 275
2023
Q4 		– Sell
-55,262
Closed -$982K – 599
2023
Q3 		$982K Sell
55,262
-48,000
-46% -$849K 0.02% 334
2023
Q2 		$1.87M Buy
103,262
+5,087
+5% +$80.9K 0.04% 309
2023
Q1 		$1.23M Buy
+98,175
New +$1.44M 0.03% 386
2022
Q4 		– Sell
-61,000
Closed -$1.04M – 297
2022
Q3 		$1.04M Buy
+61,000
New +$969K 0.01% 742

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

UBS O'Connor's TARS Position: Q3 2025 in Review

UBS O'Connor sold out of Tarsus Pharmaceuticals (TARS) in Q3 2025, closing a stake of 11,000 shares — an estimated $446K sold.

UBS O'Connor first reported a position in TARS in Q3 2022 and held it in 5 quarters. The position peaked at $1.87M in Q2 2023. 220 funds tracked by Wall St. Rank hold TARS as of Q3 2025.

  • UBS O'Connor reported no remaining Tarsus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 11,000 Tarsus Pharmaceuticals shares in Q3 2025, an estimated $446K.
  • UBS O'Connor first reported a position in Tarsus Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • UBS O'Connor's Tarsus Pharmaceuticals position peaked at $1.87M in Q2 2023.
  • 220 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.